About Skyepharma
SkyePharma is developing small molecule-based oral and inhalation products for the treatment of various diseases. It uses its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities. Its Geomatrix and Geoclock technologies enable controlled and timed-release versions of orally administered therapeutics Soctec, a novel gastric retention technology was specifically developed for molecules requiring absorption in the stomach or upper part of the intestine. Its inhalation technologies include formulation as well as device technologies and encompass Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs)
- Headquarter London, United Kingdom
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$38.7 M (USD), Debt – Conventional
May 12, 2015
-
Investors
Barclays
& 1 more
-
Employee Count
Not available
-
Acquired by
& 1 more
(Jun 24, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Skyepharma
Investors in Skyepharma
Skyepharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Barclays and Phillips Medisize.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified financial services are provided across global markets.
|
Locked | Locked | Locked | |
|
Inhaled therapeutics for respiratory diseases are developed.
|
Locked | Locked | Locked |
Investor details for Skyepharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Skyepharma
Investment portfolio details for Skyepharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Skyepharma
Detailed financials for Skyepharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Skyepharma Comparisons
Peer comparison for Skyepharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Skyepharma
Detailed competitors of Skyepharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Skyepharma
Complete news archive for Skyepharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Skyepharma
Skyepharma was founded in 1996 and raised its 1st funding round 10 years after it was founded.
Skyepharma is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
SkyePharma is developing small molecule-based oral and inhalation products for the treatment of various diseases. It uses its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities. Its Geomatrix and Geoclock technologies enable controlled and timed-release versions of orally administered therapeutics Soctec, a novel gastric retention technology was specifically developed for molecules requiring absorption in the stomach or upper part of the intestine. Its inhalation technologies include formulation as well as device technologies and encompass Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs).
Skyepharma has 2 investors. Key investors include Barclays, and Phillips Medisize.